



● c-Met inhibitors

Discovery	Cat.No.	Product Name	Information						Clinical Trial
2007	S1068	Crizotinib <small>Licensed by Pfizer</small>	Targets	c-Met	ALK				Phase 1/2
2009	S1111	Foretinib <small>(GSK1363089)</small>	Targets	Met	KDR			Others	Phase 2
2003	S1070	PHA-665752	Targets	c-Met				Others	
2009	S1561	BMS-777607	Targets	c-Met	Axl	Ron	Tyro3	Others	Phase 1/2
2010	S2753	Tivantinib <small>(ARQ 197)</small>	Targets	c-Met				Others	Phase 3
2011	S1119	Cabozantinib <small>(XL184, BMS-907351)</small>	Targets	c-Met	VEGFR2	Ret	Kit	Others	Phase 2
2011	S2788	INCB28060	Targets	c-Met				Others	Phase 1
2009	S1112	SGX-523	Targets	Met				Ron	Phase 1
2008	S1114	JNJ-38877605	Targets	c-Met					Phase 1
2003	S1080	SU11274	Targets	Met					
2009	S1094	PF-04217903	Targets	c-Met					Phase 1
2009	S1124	BMS-754807	Targets	Met	IGF-1R	IR		Others	Phase 2
2012	S1361	MGCD-265	Targets	c-Met	VEGFR1/2/3			Others	Phase 1/2
2010	S2859	Golitinib <small>(E7050)</small>	Targets	c-Met	VEGFR2			Ron, Tie2	Phase 1/2